FindTrial
Sign In

COVID-19 Infection in Patients With Hepatocellular Carcinoma

Impact of COVID-19 Infection in Patients With Hepatocellular Carcinoma: An Ambispective Study Nestled in the CHIEF Cohort

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04367805
Acronym
COVID19-CHIEF
Enrollment
23
Registered
2020-04-29
Start date
2020-05-22
Completion date
2026-06-01
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, Hepatocellular Carcinoma

Keywords

Hepatocellular Carcinoma, COVID-19, Coronavirus disease 2019-Incidence

Brief summary

Since December 2019, a new disease named COVID-19 linked to a new coronavirus, SARS-CoV2 has emerged in China in the city of Wuhan, Hubei province, spreading very quickly to all 5 continents, and responsible for a pandemic. France is the third most affected country in Europe after Italy and Spain. Groups of patients at a higher risk of developing a severe form of COVID-19 have been defined: this include patients with immunosuppressive disease as cancer or patients with advanced cirrhosis of the liver. Coronavirus liver injury had been described with SARS-CoV 1 and MERS-CoV. There is no data on liver damage associated with COVID-19 infection for compensated or decompensated cirrhotic patients. The objectives of this project are to estimate the incidence of COVID-19 in hepatocellular carcinoma population, both hospital and ambulatory, and to study the impact on the frequency of severe forms, the prognosis, but also liver function, and the management of hepatocellular carcinoma, in this context of pandemic

Interventions

DIAGNOSTIC_TESTnasopharyngeal Covid 19 RT-PCR

nasopharyngeal Covid 19 RT-PCR

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER
Centre Hospitalier-Universitaire Bondy
CollaboratorUNKNOWN
University Hospital, Bordeaux
CollaboratorOTHER
Centre Hospitalier-Universitaire CLICHY
CollaboratorUNKNOWN
Centre Hospitalier Général CORBEIL-ESSONNE
CollaboratorUNKNOWN
CHU CRETEIL
CollaboratorUNKNOWN
University Hospital, Grenoble
CollaboratorOTHER
University Hospital, Lille
CollaboratorOTHER
Hospices Civils de Lyon
CollaboratorOTHER
Poitiers University Hospital
CollaboratorOTHER
Rennes University Hospital
CollaboratorOTHER
University Hospital, Rouen
CollaboratorOTHER
University Hospital, Toulouse
CollaboratorOTHER
CHU VILLEJUIF
CollaboratorUNKNOWN
Central Hospital, Nancy, France
CollaboratorOTHER
Centre Hospitalier Universitaire de Nice
CollaboratorOTHER
University Hospital, Montpellier
CollaboratorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with CHC and included in the French national prospective cohort CHIEF * Hospital and ambulatory patients * Infection confirmed by COVID-19 defined by a positive nasopharyngeal PCR or if PCR COVID-19 negative : CT showing COVID-19 compatible pneumonia * Suspected COVID-19 infection, not confirmed by COVID-19 PCR or chest CT, with no other known cause of acute pneumonia.

Exclusion criteria

* Patient refusal * Influenza only, confirmed by a diagnostic test * Other proven causes of pneumonia and absence of COVID-19

Design outcomes

Primary

MeasureTime frameDescription
Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France6 monthsIncidence of COVID-19 infection in patients with hepatocellular carcinoma in France

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 16, 2026